(1) Stock-based compensation expense recognized in connection with the vesting and settlement of RSUs that had previously met the time vesting condition and for which the liquidity event vesting condition was satisfied in connection with our IPO.
(2) Employer payroll taxes related to the vesting and settlement of RSUs, that had previously met the time vesting condition and for which the liquidity event vesting condition was satisfied in connection with our IPO.
(3) For the three months ended March 31, 2024, the non-GAAP tax rate of approximately 22% is calculated based on the tax laws in the jurisdictions in which we operate and exclude the impact of stock-based compensation expense and associated employer payroll taxes. The adjustments for the three months ended December 31, 2023 and March 31, 2023 were not material.
(4) GAAP basic and diluted net income per share attributable to common stockholders for the three months ended December 31, 2023 was zero as all net income was attributable to preferred stockholders.
(5) Reconciliation of GAAP weighted-average shares to pro forma Non-GAAP weighted-average shares. We present the pro-forma non-GAAP weighted-average shares to provide meaningful supplemental information of comparable shares for each periods presented. The pro forma weighted-average shares is calculated as follows:
|
|
Three Months Ended |
|||||||
|
|
March 31,
|
|
December 31,
|
|
March 31,
|
|||
Shares used to compute GAAP net (loss) income per share attributable to common stockholders - diluted |
|
52,532 |
|
47,636 |
|
35,826 |
|||
Weighted-average effect of the assumed conversion of redeemable convertible preferred stock from the beginning of the quarter |
|
78,905 |
|
|
90,891 |
|
|
90,891 |
|
Effect of potentially dilutive equivalent shares |
|
16,077 |
|
|
— |
|
|
— |
|
Shares used to compute pro forma non-GAAP net income (loss) per share- diluted |
|
147,514 |
|
|
138,527 |
|
|
126,717 |
|
ASTERA LABS, INC. SUPPLEMENTAL FINANCIAL INFORMATION STOCK-BASED COMPENSATION EXPENSE (Unaudited) (In thousands) |
||||||||||||
|
Three Months Ended |
|||||||||||
|
March 31,
|
|
December 31,
|
|
March 31,
|
|||||||
Cost of revenue |
$ |
528 |
|
$ |
8 |
|
$ |
5 |
||||
| Research and development |
|
30,007 |
|
|
|
2,303 |
|
|
|
1,679 |
|
|
| Sales and marketing |
|
49,258 |
|
|
|
681 |
|
|
|
1 |
|
|
| General and administrative |
|
17,975 |
|
|
|
307 |
|
|
|
312 |
|
|
| Total stock-based compensation expense (1) |
$ |
97,768 |
|
|
$ |
3,299 |
|
|
$ |
1,997 |
|
|
